AGM
IKT icon

Alpine Global Management’s Inhibikase Therapeutics IKT Stock Holding History

Alpine Global Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-29,684
Closed -$96.5K – 192
2024
Q4 		$96.5K Buy
+29,684
New +$74K 0.01% 188

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Alpine Global Management's IKT Position: Q1 2025 in Review

Alpine Global Management sold out of Inhibikase Therapeutics (IKT) in Q1 2025, closing a stake of 29,684 shares — an estimated $96.5K sold.

Alpine Global Management first reported a position in IKT in Q4 2024 and held it in 1 quarter. The position peaked at $96.5K in Q4 2024. 47 funds tracked by Wall St. Rank hold IKT as of Q1 2025.

  • Alpine Global Management reported no remaining Inhibikase Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Alpine Global Management sold 29,684 Inhibikase Therapeutics shares in Q1 2025, an estimated $96.5K.
  • Alpine Global Management first reported a position in Inhibikase Therapeutics in Q4 2024 and held it in 1 quarter.
  • Alpine Global Management's Inhibikase Therapeutics position peaked at $96.5K in Q4 2024.
  • 47 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2025.

Based on Alpine Global Management's 13F filing for Q1 2025, filed 15 May 2025.